Slide 1: Jupiter Neurosciences, Inc. (NASDAQ: JUNS)
Jupiter Neurosciences, Inc. (NASDAQ: JUNS)
Slide 2: Cautionary Note on Forward Looking Statements
CAUTIONARY NOTE ON FORWARD LOOKING STATEMENTS This Presentation contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about
Slide 3: Investment Highlights
Investment Highlights Significant research and corporate accomplishments; positioned to execute several steps in 2025 and 2026 Breakthrough Therapeutics Platform — JOTROL : Proprietary micellar resveratrol delivery system achieves ~9× higher bioavailability, penetrates the CNS, is patent-protected t
Slide 4: JOTROL - Broad Applicability Across Disease Areas
JOTROL - Broad Applicability Across Disease Areas JOTROL ’s micellar system allows therapeutic dosing without gastrointestinal toxicity, a major barrier for competitors, giving Jupiter a defensible IP position and potential for regulatory approvals across indications. Alzheimer's Disease Parkinson's
Slide 5: Comprehensive R&D Pipeline
Comprehensive R&D Pipeline One completed Phase I (healthy volunteers) is the safety/tolerability gate that lets multiple programs start at Phase II Lead program – Parkinson’s disease: Present focus; advancing into Phase II based on supportive preclinical results Why PD first - In the established MPT
Slide 6: Phase IIA JOTROL PD Study
Phase IIA JOTROL PD Study ➢ Milestones • IND granted Oct 2025 • GMP material production complete • Trial activation ongoing • FPI expected late Q1/early Q2 2026 ➢ Trial Design • 30 PD patients • Randomized into placebo/MAD design • Oral administration of study drug • Once daily administration over t
Slide 7: Nugevia - DTC Consumer Supplements
Nugevia - DTC Consumer Supplements Nugevia isn’t just Jupiter’s consumer brand, it’s a dual-purpose platform that delivers high-margin revenue today while generating real-world data that strengthens clinical trials. • Launched in Q3 2025, Nugevia positions Jupiter in the $8 trillion global longevity
Slide 8: Management
Management Strong management team and advisors with extensive international experience and a track record for successfully building organizations that can take a product from inception to commercialization. Christer ”Chris” Rosén Alexander Rosén Marshall Hayward, Ph.D Alison D. Silva Saleem Emasri,
Slide 9: Scientific Advisory Board
Scientific Advisory Board Scientific Team comprising of world-renowned specialists in their respective fields, providing hands-on involvement and valuable assistance to JUNS. Li-Huei Tsai, Raymond Turner, Charbel Moussa, W. Dalton Ditreich III, Shaun Brothers, Claes Wahlestedt, 4 Ph.D. MD, Ph.D. MBB
Slide 10: NASDAQ: JUNS
NASDAQ: JUNS Contacts: c.rosen@Jupiterneurosciences.com a.rosen@jupiterneurosciences.com a.silva@jupiterneurosciences.com